P2Y12 inhibitors are a class of antiplatelet medications that block the P2Y12 receptor on platelets, preventing platelet aggregation and reducing the risk of thrombotic events such as heart attacks and strokes.

• Clopidogrel – A prodrug requiring hepatic activation, commonly used in preventing cardiovascular events.
• Prasugrel – More potent than clopidogrel, with a faster onset and greater efficacy but higher bleeding risk.
• Ticagrelor – A reversible inhibitor that does not require metabolic activation, offering a more predictable response.
• Cangrelor – An intravenous P2Y12 inhibitor used in acute settings for rapid platelet inhibition.

• Acute Coronary Syndromes (ACS) – Used to prevent clot formation in patients with unstable angina or myocardial infarction.
• Percutaneous Coronary Intervention (PCI) – Administered alongside aspirin to reduce thrombotic complications post-stent placement.
• Secondary Stroke Prevention – Sometimes used in combination with aspirin for short-term dual antiplatelet therapy (DAPT).